Eyepoint Pharmaceuticals Net Income
| EYPT Stock | USD 14.36 0.55 3.69% |
As of the 18th of February 2026, Eyepoint Pharmaceuticals shows the Downside Deviation of 3.58, coefficient of variation of 1241.84, and Mean Deviation of 3.46. Eyepoint Pharmaceuticals technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Eyepoint Pharmaceuticals Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 20.9865 | Revenue | Earnings Share (3.00) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -117.8 M | -111.9 M | |
| Net Loss | -92 M | -87.4 M | |
| Net Loss | -117.8 M | -111.9 M | |
| Net Loss | (2.09) | (2.20) | |
| Net Income Per E B T | 0.90 | 0.71 |
Eyepoint | Net Income | Build AI portfolio with Eyepoint Stock |
The evolution of Net Income for Eyepoint Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Eyepoint Pharmaceuticals compares to historical norms and industry peers.
Latest Eyepoint Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Eyepoint Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Eyepoint Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Eyepoint Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Eyepoint Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eyepoint Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (130.87 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Eyepoint Net Income Regression Statistics
| Arithmetic Mean | (49,530,904) | |
| Geometric Mean | 30,724,890 | |
| Coefficient Of Variation | (88.39) | |
| Mean Deviation | 35,968,190 | |
| Median | (45,394,000) | |
| Standard Deviation | 43,782,009 | |
| Sample Variance | 1916.9T | |
| Range | 137.2M | |
| R-Value | (0.91) | |
| Mean Square Error | 363.3T | |
| R-Squared | 0.82 | |
| Slope | (7,862,251) | |
| Total Sum of Squares | 30669.8T |
Eyepoint Net Income History
Other Fundumenentals of Eyepoint Pharmaceuticals
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Eyepoint Pharmaceuticals Net Income component correlations
Eyepoint Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Eyepoint Pharmaceuticals is extremely important. It helps to project a fair market value of Eyepoint Stock properly, considering its historical fundamentals such as Net Income. Since Eyepoint Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eyepoint Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eyepoint Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Pharmaceuticals market expansion? Will Eyepoint introduce new products? Factors like these will boost the valuation of Eyepoint Pharmaceuticals. Projected growth potential of Eyepoint fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Eyepoint Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.00) | Revenue Per Share | Quarterly Revenue Growth (0.91) | Return On Assets | Return On Equity |
The market value of Eyepoint Pharmaceuticals is measured differently than its book value, which is the value of Eyepoint that is recorded on the company's balance sheet. Investors also form their own opinion of Eyepoint Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eyepoint Pharmaceuticals' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Eyepoint Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eyepoint Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Eyepoint Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Eyepoint Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Eyepoint Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Eyepoint Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Eyepoint Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Eyepoint Pharmaceuticals.
| 11/20/2025 |
| 02/18/2026 |
If you would invest 0.00 in Eyepoint Pharmaceuticals on November 20, 2025 and sell it all today you would earn a total of 0.00 from holding Eyepoint Pharmaceuticals or generate 0.0% return on investment in Eyepoint Pharmaceuticals over 90 days. Eyepoint Pharmaceuticals is related to or competes with ProKidney Corp, Kura Oncology, Bicara Therapeutics, Kodiak Sciences, Tango Therapeutics, Septerna Common, and Prime Medicine. EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatm... More
Eyepoint Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Eyepoint Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Eyepoint Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.58 | |||
| Information Ratio | 0.0706 | |||
| Maximum Drawdown | 23.49 | |||
| Value At Risk | (4.98) | |||
| Potential Upside | 8.15 |
Eyepoint Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Eyepoint Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Eyepoint Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Eyepoint Pharmaceuticals historical prices to predict the future Eyepoint Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0721 | |||
| Jensen Alpha | 0.3763 | |||
| Total Risk Alpha | 0.151 | |||
| Sortino Ratio | 0.0928 | |||
| Treynor Ratio | (1.87) |
Eyepoint Pharmaceuticals February 18, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0721 | |||
| Market Risk Adjusted Performance | (1.86) | |||
| Mean Deviation | 3.46 | |||
| Semi Deviation | 3.29 | |||
| Downside Deviation | 3.58 | |||
| Coefficient Of Variation | 1241.84 | |||
| Standard Deviation | 4.71 | |||
| Variance | 22.16 | |||
| Information Ratio | 0.0706 | |||
| Jensen Alpha | 0.3763 | |||
| Total Risk Alpha | 0.151 | |||
| Sortino Ratio | 0.0928 | |||
| Treynor Ratio | (1.87) | |||
| Maximum Drawdown | 23.49 | |||
| Value At Risk | (4.98) | |||
| Potential Upside | 8.15 | |||
| Downside Variance | 12.83 | |||
| Semi Variance | 10.8 | |||
| Expected Short fall | (4.17) | |||
| Skewness | 1.15 | |||
| Kurtosis | 2.1 |
Eyepoint Pharmaceuticals Backtested Returns
Currently, Eyepoint Pharmaceuticals is not too volatile. Eyepoint Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.0409, which denotes the company had a 0.0409 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Eyepoint Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please confirm Eyepoint Pharmaceuticals' Mean Deviation of 3.46, downside deviation of 3.58, and Coefficient Of Variation of 1241.84 to check if the risk estimate we provide is consistent with the expected return of 0.18%. Eyepoint Pharmaceuticals has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.2, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Eyepoint Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Eyepoint Pharmaceuticals is likely to outperform the market. Eyepoint Pharmaceuticals right now shows a risk of 4.48%. Please confirm Eyepoint Pharmaceuticals downside variance, and the relationship between the total risk alpha and daily balance of power , to decide if Eyepoint Pharmaceuticals will be following its price patterns.
Auto-correlation | -0.81 |
Excellent reverse predictability
Eyepoint Pharmaceuticals has excellent reverse predictability. Overlapping area represents the amount of predictability between Eyepoint Pharmaceuticals time series from 20th of November 2025 to 4th of January 2026 and 4th of January 2026 to 18th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Eyepoint Pharmaceuticals price movement. The serial correlation of -0.81 indicates that around 81.0% of current Eyepoint Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.81 | |
| Spearman Rank Test | -0.64 | |
| Residual Average | 0.0 | |
| Price Variance | 2.25 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Eyepoint Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Eyepoint Pharmaceuticals reported net income of (130.87 Million). This is 138.35% lower than that of the Pharmaceuticals sector and 286.84% lower than that of the Health Care industry. The net income for all United States stocks is 122.92% higher than that of the company.
Eyepoint Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eyepoint Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eyepoint Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eyepoint Pharmaceuticals by comparing valuation metrics of similar companies.Eyepoint Pharmaceuticals is currently under evaluation in net income category among its peers.
Eyepoint Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Eyepoint Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eyepoint Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Eyepoint Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Eyepoint Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Eyepoint Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Eyepoint Pharmaceuticals' value.| Shares | Patient Square Capital | 2025-06-30 | 1.4 M | Goldman Sachs Group Inc | 2025-06-30 | 1.3 M | Essex Woodlands Health Ventures | 2025-06-30 | 1.2 M | 5am Venture Management, Llc | 2025-06-30 | 1.1 M | Aberdeen Group Plc | 2025-06-30 | 1 M | Bank Of America Corp | 2025-06-30 | 814.2 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 782.6 K | Hsbc Holdings Plc | 2025-06-30 | 631.1 K | Nantahala Capital Management, Llc | 2025-06-30 | 593.1 K | Cormorant Asset Management, Llc | 2025-06-30 | 8.3 M | Suvretta Capital Management, Llc | 2025-06-30 | 6.8 M |
Eyepoint Fundamentals
| Return On Equity | -0.98 | ||||
| Return On Asset | -0.49 | ||||
| Operating Margin | (64.21) % | ||||
| Current Valuation | 888.55 M | ||||
| Shares Outstanding | 82.79 M | ||||
| Shares Owned By Insiders | 2.76 % | ||||
| Shares Owned By Institutions | 95.83 % | ||||
| Number Of Shares Shorted | 8.64 M | ||||
| Price To Earning | (2.82) X | ||||
| Price To Book | 5.35 X | ||||
| Price To Sales | 29.15 X | ||||
| Revenue | 43.27 M | ||||
| Gross Profit | (161.42 M) | ||||
| EBITDA | (129.23 M) | ||||
| Net Income | (130.87 M) | ||||
| Cash And Equivalents | 171.17 M | ||||
| Cash Per Share | 5.02 X | ||||
| Total Debt | 21.86 M | ||||
| Debt To Equity | 0.30 % | ||||
| Current Ratio | 6.16 X | ||||
| Book Value Per Share | 2.88 X | ||||
| Cash Flow From Operations | (126.23 M) | ||||
| Short Ratio | 9.44 X | ||||
| Earnings Per Share | (3.00) X | ||||
| Target Price | 36.08 | ||||
| Number Of Employees | 165 | ||||
| Beta | 1.79 | ||||
| Market Capitalization | 1.23 B | ||||
| Total Asset | 418.46 M | ||||
| Retained Earnings | (873.02 M) | ||||
| Working Capital | 334.26 M | ||||
| Current Asset | 15.08 M | ||||
| Current Liabilities | 11.26 M | ||||
| Net Asset | 418.46 M |
About Eyepoint Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eyepoint Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eyepoint Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eyepoint Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Eyepoint Stock Analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.